The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Management of hypertension in angiogenesis inhibitor-treated patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266 · cited 1×
“Careful attention to patients in the prehypertension category is important because several studies indicate that mortality rates for myocardial infarctions, strokes, and other vascular diseases increase progressively with a rise in BP and can begin at levels as low as 115/75 mmHg [26].”
BackgroundA Clinical Trial of the Effects of Dietary Patterns on Blood Pressure
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361601 · Cited by 5,981
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry
Piccirillo, J. F. (2004) · JAMA · doi:10.1001/jama.291.20.2441 · Cited by 1,205
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025
VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h1054 · Cited by 699
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688
Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., & Kalluri, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300012200 · Cited by 538
Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., Liang, C., Booth, B., Chidambaram, N., Morse, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1249 · Cited by 474
Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70003-2 · Cited by 386
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
(2006) · New England Journal of Medicine · doi:10.1056/nejmc052954 · Cited by 365
Mourad, J.-J., des Guetz, G., Debbabi, H., & Levy, B. I. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm550 · Cited by 306
Drevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303
Managing Patients Treated with Bevacizumab Combination Therapy
Gordon, M. S., & Cunningham, D. (2005) · Oncology · doi:10.1159/000088481 · Cited by 283
Horowitz, J. R., Rivard, A., van der Zee, R., Hariawala, M., Sheriff, D. D., Esakof, D. D., Chaudhry, G. M., Symes, J. F., & Isner, J. M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.2793 · Cited by 266
Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
Ahmad, T., & Eisen, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040028 · Cited by 244
Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 213
Hecht, J. R., Trarbach, T., Jaeger, E., Hainsworth, J., Wolff, R., Lloyd, K., Bodoky, G., Borner, M., Laurent, D., & Jacques, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba3 · Cited by 201
Home Blood-Pressure Monitoring in Patients Receiving Sunitinib
Azizi, M., Chedid, A., & Oudard, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc072330 · Cited by 197
Angiogenic growth factors and hypertension
Sane, D. C., Anton, L., & Brosnihan, K. B. (2004) · Angiogenesis · doi:10.1007/s10456-004-2699-3 · Cited by 195
Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension
Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., & Deray, G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.025 · Cited by 186
Self-citationManegold, C., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsch, V., Leighl, N., Mezger, J., Archer, V., & Reck, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.lba7514 · Cited by 168
Hypertension as a predictive factor of Sunitinib activity
Rixe, O., Billemont, B., & Izzedine, H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm184 · Cited by 166
Self-citationCanoy, D., Luben, R., Welch, A. A., Bingham, S. A., Wareham, N. J., Day, N., & Khaw, K. (2004) · Journal of Hypertension · doi:10.1097/00004872-200411000-00007 · Cited by 157
Porta, C., Paglino, C., Imarisio, I., & Bonomi, L. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0145-8 · Cited by 147
Hochster, H. S., Hart, L. L., Ramanathan, R. K., Hainsworth, J. D., Hedrick, E. E., & Childs, B. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3510 · Cited by 135
Knowledge of renal histology alters patient management in over 40% of cases
Richards, N. T., Darby, S., Howie, A. J., Adu, D., & Michael, J. (1994) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/9.9.1255 · Cited by 127
Laurie, S. A., Gauthier, I. C., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E. X., Goss, G. D., Powers, J., Walsh, W., Tu, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4741 · Cited by 119
Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006
Govindarajan, R., Adusumilli, J., Baxter, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4608 · Cited by 106
Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension
Oliver, J. J., Melville, V., & Webb, D. J. (2006) · Hypertension · doi:10.1161/01.hyp.0000239816.13007.c9 · Cited by 104
Reversible Posterior Leukoencephalopathy Syndrome Induced by Sunitinib
Martin, G., Bellido, L. M., & Cruz, J. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8710 · Cited by 102
Koehne, C., Bajetta, E., Lin, E. H., Cutsem, E. V., Hecht, J. R., Douillard, J., Moore, M. J., Germond, C. J., Laurent, D., & Jacques, C. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3508 · Cited by 91
Hedrick, E. E., Kozloff, M. F., Hainsworth, J. D., Badarinath, S., Cohn, A. L., Flynn, P. J., Dong, W., Suzuki, S., Sugrue, M. M., & Grothey, A. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3536 · Cited by 89
ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis
Blanco, S., Bonet, J., López, D., Casas, I., & Romero, R. (2004) · Kidney International · doi:10.1111/j.1523-1755.2005.09303.x · Cited by 59
National Cancer Institute (U.S.) (2013) · Springer eBooks · doi:10.1007/978-3-642-28753-4_200424 · Cited by 51
Köhne, C.-H., Bajetta, E., Lin, E. H., Valle, J. W., Cutsem, E. V., Hecht, J. R., Moore, M., Germond, C. J., Meinhardt, G., & Jacques, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4033 · Cited by 47
Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
Dirix, L. Y., Maes, H., & Sweldens, C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm205 · Cited by 45
Agabiti‐Rosei, E. (2003) · Drugs · doi:10.2165/00003495-200363991-00003 · Cited by 39
Agabiti‐Rosei, E. (2003) · PubMed · Cited by 34
Molteni, A., Heffelfinger, S. C., Moulder, J. E., Uhal, B. D., & Castellani, W. J. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778226521 · Cited by 34
Siddiqui, A. J., Månsson‐Broberg, A., Gustafsson, T. P., Grinnemo, K., Dellgren, G., HAO, X., Fischer, H., & Sylvén, C. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.04.023 · Cited by 28
Hypertension Associated With Bevacizumab
Rosiak, J., & Sadowski, L. (2005) · Clinical journal of oncology nursing · doi:10.1188/05.cjon.407-411 · Cited by 15
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Metadata
- Authors
- Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 20
- Issue
- 5
- Pages
- 807-815
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2122724278
- Cited by
- 347
- References
- 58
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.